Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3NETWORK 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 6Burkitt Lymphoma 5Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Myelodysplastic Syndromes 2Anemia, Refractory, with Excess of Blasts 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Down Syndrome 1Anemia, Refractory 1

Interventions

Cytarabine 61Daunorubicin 28Specimen Handling 24Etoposide 24Azacitidine 22Decitabine 19Cyclophosphamide 19fludarabine phosphate 18Filgrastim 18Biopsy 18Busulfan 17Idarubicin 16venetoclax 15Peripheral Blood Stem Cell Transplantation 15Mitoxantrone 15Injections 14Vorinostat 12tipifarnib 11Bortezomib 10decitabine and cedazuridine drug combination 9Radiotherapy 9Methotrexate 9alvocidib 8Cyclosporine 8sargramostim 7Melphalan 7Antilymphocyte Serum 7laromustine 6fludarabine 6aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Acute × Hydrocortisone × Clear all
NCT03813147 2025-04-13

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡